A Scrap over Sequences, Take Two

Science magazine's controversial decision to publish the Syngenta draft rice genome sequence without requiring the company to deposit its data in a public database is getting less than rave reviews from scientists who need to use the genome map in their work. Over the objections of leading scientists who warn that scientific publishing principles have been sacrificed to commercial gain, Science allowed the agrochemical giant based in Basel, Switzerland, to maintain control of its data when it un

Written byPeg Brickley
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Syngenta declined to deposit its data in GenBank, the open public storehouse of genetic material. A Chinese-led team of academics published a blueprint of the indica strain of rice in the same issue, and that map will be available on Genbank.2 "It's a fundamental principle of scientific publication that you provide the data and that science can build on it," says Robert H. Waterston of the Washington University, one of 19 leading scientists who signed a letter protesting Science's special arrangement with Syngenta. "This has been a procedure that has worked very well over several hundred years."

The journal's editor-in-chief Donald A. Kennedy says Syngenta had set up a system of data access that met Science's standards, including what seemed to be open release to academic researchers. The compromise, he says, was necessary to give academic researchers as much access as possible to the genetic data for the most important ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies